anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A dihydrobenzofuranone derivative expressed by formula I (R<1> is H or lower alkoxy; R<2> and R<3> are H or lower alkyl; formula II is piperidino or morpholino; Y is OH or acetoxy). EXAMPLE:4-[3-(2,3-Dihydro-2-hydroxymethyl-2-methyl-3-oxo-5-benzofuranyl) acryloyl]morpholine. USE:A medicine. A remedy for gastric and duodenal ulcer exhibiting strong antistress ulcer action and having low toxicity. PREPARATION:A novel compound expressed by formula III is reacted with formaldehyde in the presence of a base such as NaOH to provide the compound expressed by formula I (Y is OH). Further, a novel compound expressed by formula IV is reacted with a compound expressed by formula V in the presence of a base such as triethylamine, palladium acetate and triphenylphosphine or tris(2-methylphenyl)phosphine to provide the compound expressed by formula I (Y is acetoxy).
The present invention relates to a medicinal composition for treating beriberic and a preparation method thereof. The Chinese medicinal composition comprises washing medicine and dressing medicine, wherein the washing medicine mainly comprises herba agastachis, Chinese atractylodes, fried achene of Siberian cocklebur, notopterygium root, china root and rose-of-sharon root bark; the dressing medicine mainly comprises phellodendron bark, radix sophorae flavescentis, dried alum and chlortrimeton. During preparation, firstly, raw material of the washing medicine is uniformly mixed, and the washing medicine is obtained by pulverization after the mixture is dried; simultaneously, the dressing medicine is obtained by pulverization after each raw material of the dressing medicine is uniformly mixed. The medicinal composition of the present invention for treating beriberi has a reasonable formula, obvious effect, unique effect on ulcer, itch, osmyl, pain, etc. of various kinds of beriberi and no damage to skin; generally, the medicinal composition takes effect once, and beriberi can be cured for 2 to 3 times. According to clinical experiment summaries of more than 2000 persons for many years, the total effective rate reaches more than 98%; the present invention also has the advantages of simple preparation, convenient use and no toxic or side effect.
REACH will serve a minimum of 337 individual adults during each full year of the five-year grant term in Sarasota, Manatee, and Charlotte counties on the Gulf Coast of Florida. REACH will target individual participants and, in cases where both members of a couple are interested in participating, will deliver services to each partner individually. The primary target population for REACH is low-income, at-risk individuals.

Coupled with its successful history of providing healthy marriage programming, JFCS is well-positioned to help families in crisis become more stable and self-sufficient. Understanding the inextricable link between financial security and family stability, REACH is targeting and reaching the most vulnerable individuals based solely on economic risk factors. REACH will incorporate a comprehensive employment program combining both job and career advancement. This will help families in crisis reach improved financial stability, which will in turn improve the ability of individual participants to be better parents and better partners, furthering the goal of promoting healthy marriages and reducing local divorce rates.
The approval of the glucagon-like peptide 1 (GLP-1) mimetics semaglutide and liraglutide for management of obesity, independent of type 2 diabetes (T2DM), has initiated a resurgence of interest in gut-hormone derived peptide therapies for the management of metabolic diseases, but side-effect profile is a concern for these medicines. However, the recent approval of tirzepatide for obesity and T2DM, a glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor co-agonist peptide therapy, may provide a somewhat more tolerable option. Despite this, an increasing number of non-incretin alternative peptides are in development for obesity, and it stands to reason that other hormones will take to the limelight in the coming years, such as peptides from the neuropeptide Y family. This narrative review outlines the therapeutic promise of the neuropeptide Y family of peptides, comprising of the 36 amino acid polypeptides neuropeptide Y (NPY), peptide tyrosine-tyrosine (PYY) and pancreatic polypeptide (PP), as well as their derivatives. This family of peptides exerts a number of metabolically relevant effects such as appetite regulation and can influence pancreatic beta-cell survival. Although some of these actions still require full translation to the human setting, potential therapeutic application in obesity and type 2 diabetes is conceivable. However, like GLP-1 and GIP, the endogenous NPY, PYY and PP peptide forms are subject to rapid in vivo degradation and inactivation by the serine peptidase, dipeptidyl-peptidase 4 (DPP-4), and hence require structural modification to prolong circulating half-life. Numerous protective modification strategies are discussed in this regard herein, alongside related impact on biological activity profile and therapeutic promise.
BACKGROUND: An association between variability of cardiovascular risk factors and cardiovascular events has been reported. We examined whether intensive lifestyle intervention (ILI) for weight loss decreased variability of cardiovascular risk factors with a view to additional cardiometabolic benefits.
METHODS AND RESULTS: This study was a post hoc secondary analysis of the Look AHEAD (Action for Health in Diabetes) study. Cardiovascular risk factors were measured at 1-year intervals for 4 years in 4249 adults with overweight or obesity and type 2 diabetes who were randomly assigned to ILI or diabetes support and education. Long-term variability was defined as the SD of cardiovascular risk factors during 4-year follow-up. At multiple linear regression analysis, compared with the diabetes support and education group, the ILI group was associated with reduced variability of fasting blood glucose (β=-1.49 [95% CI, -2.39 to -0.59]), total cholesterol (β=-1.12 [95% CI, -1.75 to -0.48]), and low-density lipoprotein cholesterol (β=-1.04 [95% CI, -1.59 to -0.49]), as well as increased variability of systolic blood pressure (β=0.27 [95% CI, 0.00-0.54]). No significant effect of ILI was found on the variability of diastolic blood pressure (β=-0.08 [95% CI, -0.22 to 0.05]).
CONCLUSIONS: Among adults with overweight or obesity and type 2 diabetes, ILI may reduce long-term variability of fasting blood glucose, total cholesterol, and low-density lipoprotein cholesterol. Our results support that ILI should be recommended to individuals with diabetes as part of management of long-term glycemic and blood lipid control.
BACKGROUND: The presence of untreated sexually transmitted infections (STIs) significantly increases the chance of acquiring HIV. In Brazil, testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) among Pre-Exposure Prophylaxis (PrEP) users is insufficient, and syndromic treatment is a priority in clinical practice. Multi-site testing for CT/NG improves thescreening of asymptomatic cases and ensures timely treatment. Therefore, it is essential for HIV prevention. This study aims to test the importance of two-site testing for better screening of these pathogens and to determine whether the presence of symptoms is an indicator of CT/NG infection.
METHODS: This is a cross-sectional study carried out in four public infectious diseases clinics in São Paulo State, Brazil between January of 2022 and March of 2023. All participants had an anal swab and a first-pass or mid-stream urine collected for CT/NG analysis by Polymerase chain reaction (PCR). Data about sociodemographic, sexual behavioural and clinical aspects were collected. Pathway analysis was used to examine the direct and indirect relationships between variables according to the theoretical model.
RESULTS: We screened 171 PrEP users which had two samples collected, resulting in 342 samples. Comparing the anatomic sites, the urine samples showed lower sensitivity for CT and NG than anal samples. Gonorrhoea was directly linked to lower age (β= -0.161, p = 0.001). Time of PrEP use was directly associated with CT infection (β = 0.202; p = 0.042) and inversely associated with dysuria (β= -0.121, p = 0.009). Lower occurrence of yellow-green secretion was linked to detection of CT (β= -0.089, p = 0.005) and NG (β= -0.048, p = 0.002) infections. Foul-smelling discharge was directly associated with CT (β = 0.275, p = 0.004) and NG (β = 0.295, p = 0.037) infection.
CONCLUSION: The symptoms are a bad indicator of CT and NG infection, and the screening must be done in more than one site since most of the positive results would be missed if only urines were tested. In the case of testing only one anatomical site, specifically the urethra, the CT/NG incidence and prevalence would be underestimated. The two-sites testing improves detection rates of CT/NG, and PrEP follow-up benefits people offering STI testing.
American Society for Pain Management Nursing (ASPMN) supports safe medication practices and the appropriate use of pro re nata (PRN) range orders for analgesics in the management of pain within the scope of nursing practice. Although range orders may apply to many medications prescribed as PRN, the focus of this ASPMN position statement is on PRN analgesic medication. PRN range orders are commonly used to provide flexibility in dosing to meet the analgesic requirements of an individual patient. There are many patient-specific factors that require professional clinical assessment when administering medications to patients. Unfortunately, several myths persist regarding The Joint Commission's (TJC) standard around the implementation of range orders leading many to assume that range orders are not supported or safe. On the contrary, if utilized in a consistent and appropriate manner, PRN range orders can allow nurses to provide optimal pain management while still providing safe administration (Paquette et al., 2022).
BACKGROUND: Page kidney is a rare condition in which an external compression of the kidney as a result of a hematoma or mass causes renal ischemia and hypertension. In a patient with flank pain, elevated blood pressure, and recent trauma, this condition should be considered. Since this condition was first described in 1939, more than 100 case reports have surfaced.
CASE REPORT: We describe the case of a 26-year-old man who presented to the Emergency Department with flank pain, vomiting, and elevated blood pressure. A computed tomography scan of the abdomen and pelvis confirmed the presence of a perinephric hematoma, and the interventional radiology team was consulted to resolve the Page kidney. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Symptoms seen in Page kidney may be similar to other more common diagnoses encountered in the emergency department. It is important to maintain a high suspicion and order imaging studies as needed, especially in the setting of trauma, or a recent procedure in the vicinity of the renal parenchyma.
PURPOSE:To provide a new phenylglycoside having excellent activity to suppress the isolation of histamine from mast cell and, accordingly, useful as a new antiallergic agent effective for suppressing the isolation of histamine itself from mast cell. CONSTITUTION:The phenylglycoside of formula I [X is sugar residue obtained by removing all hydroxyl groups from a sugar having (n+1) hydroxyl groups; (n) is 3 or 4; R<1> is 9-18C alkyl], e.g. 4-decyloxyphenyl-beta-D-glycopyranoside. The compound can be produced by the deacetylation of the compound of formula II The compound of formula II is obtained e.g. by reacting a monoalkylhydroquinone of formula III with a peracetylated sugar of formula IV in a non-aqueous solvent (e.g. benzene) in the presence of an organic solvent complex of a Lewis acid as a catalyst. The organic acid complex of Lewis acid is e.g. BF3.ether.
The present invention relates to a pain alleviating plaster for periarthritis of the shoulder and a preparing method thereof. The pain alleviating plaster for periarthritis of the shoulder is formed into a plaster preparation by preparing turmeric root tuber, clematis root, spinyleaf pricklyash root, olibanum, myrrh and borneol. Compared with the prior art, the product formula provided by the present invention has the advantages of simple composition, simple productive technology and easy control of product quality. The product is directly applied to the shoulder joint with pathological changes, medicines can directly reaches to diseased regions by being absorbed by the skin, so that treating purposes are achieved. The present invention has the characteristics of convenient use, stable quality, high symptom improving speed, portability, etc. The medicines contained in the product have no obvious toxic or side effect, and can be clinically used for a long time, and the security is good.
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with somatropin products. Symptoms usually occurred within the first eight (8) weeks after the initiation of somatropin therapy. In all reported cases, IH-associated signs and symptoms rapidly resolved after cessation of therapy or a reduction of the somatropin dose.

Funduscopic examination should be performed routinely before initiating treatment with somatropin to exclude preexisting papilledema, and periodically during the course of somatropin therapy. If papilledema is observed by funduscopy during somatropin treatment, treatment should be stopped. If somatropin-induced IH is diagnosed, treatment with somatropin can be restarted at a lower dose after IH-associated signs and symptoms have resolved. Patients with Turner syndrome may be at increased risk for the development of IH.
The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
The active substance preparation from herbal active substances involves utilizing stinging nettle herb, rosemary and Erica. The lime-tree blossom and Senna are also utilized. 0-100 g, preferably 50 g part by wt. of stinging nettle herb, rosemary, Erica and lime-tree blossom, and 25 g part by wt. of Senna are used with a total wt. of 225 g.
A wound care assessment system includes an image capturing device and a processor. The image capturing device is for capturing a target wound image data of a subject. The processor is signally connected to the image capturing device and includes an image-labeling module, a pre-processing module and a wound grade assessment model. The image-labeling module is for receiving and analyzing the target wound image data output from the image capturing device. The pre-processing module is signally connected to the image-labeling module. The wound grade assessment model is established by an establishing method of wound grade assessment model, and the wound grade assessment model is signally connected to the pre-processing module. The wound grade assessment model is for assessing a pressure injury stage and a wound bed preparation indicator of a wound of the subject corresponding to the target wound image data.
Chronic pain is a complex and pervasive condition that profoundly affects individuals physically, emotionally, and socially. This narrative review aims to provide internists and healthcare professionals with a comprehensive overview of chronic pain, its various types, pathophysiology, epidemiology, clinical presentation, evaluation tools, and the burden it imposes on patients. We discuss the importance of recognizing chronic pain as a legitimate condition and the need for a compassionate, individualized approach to management. The review highlights the role of both pharmacological and non-pharmacological interventions in treating chronic pain, emphasizing the value of reducing pain, improving function, enhancing quality of life, and minimizing medication dependence. Additionally, we touch upon the promising future of pain treatment, including advancements in technology and personalized medicine. While not a comprehensive systematic review, this article serves as a valuable resource for healthcare providers seeking to understand, manage, and treat chronic pain effectively in their daily practice.
The invention relates, in part, to methods and compositions for the intracellular delivery of polysaccharides. In particular, the methods and compositions relate to the intracellular delivery of glycosaminoglycans, such as heparin. The invention in other aspects relates to the use of glycosaminoglycans for the treatment of proliferative disorders, such as cancer. The invention is still other aspects relates to improving cell viability. The invention also relates to the delivery of polysaccharides while avoiding unwanted effects of the polysaccharides. For example, heparin can be delivered while avoiding its anticoagulant effects.
Therapeutic response to acarbose tablets should be monitored by periodic blood glucose tests. Measurement of glycosylated hemoglobin levels is recommended for the monitoring of long-term glycemic control.

Acarbose tablets, particularly at doses in excess of 50 mg t.i.d., may give rise to elevations of serum transaminases and, in rare instances, hyperbilirubinemia. It is recommended that serum transaminase levels be checked every 3 months during the first year of treatment with acarbose tablets and periodically thereafter. If elevated transaminases are observed, a reduction in dosage or withdrawal of therapy may be indicated, particularly if the elevations persist.

Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking acarbose. Use alternative methods to monitor for glycemic control.
Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
In a method/process for the extraction of a first plant matter(s) with an alcoholic solvent, the former is treated with a second plant matter(s) containing acidic components) that converts) one or more of the insoluble constituents thereof into soluble forms, thus enabling the extraction of a wider range of constituents. Plant species having the desired nutrients and the appropriate acidic components are reacted and extracted to give a composition containing the desired vitamins and minerals(and/or other nutrients), in substantially the desired proportions through a single extraction operation with a single solvent thus eliminating several processing steps involved in conventional processes. Suitable acidic plant matters are amla fruits, lemon peels etc. Preferred solvent is aqueous ethanol. Said acidic treatment may be carried out before or during the extraction operation. Conversion into forms having enhanced solubility and/or increased biological and metabolical activity/efficacy is also feasible.
PURPOSE:To prepare a tumor necrosis factor and to collect and to purify the titled factor in case of necessity, by treating a normal cell or a cancerated cell of a monocytic cell of a mammal or one derived from it with a specific substance. CONSTITUTION:A normal cell or its cancerated cell of a monocytic cell of a mammal (e.g., hamster, etc.) or one derived from it is transplanted into a body of a warm-blooded animal (e.g., chicken, dog, cat, bovine, horse, quinea pig, etc.) or suspended in its humors or brought into contact with it, treated with a second irritant substance (endotoxin obtained from Gram-negative or Gram-positive bacteria), to form a tumor necrosis factor (TNF). If, necessary, TNF is dialyzed, subjected to salting-out, filtered, centrifuged, concentrated, lyophilized, etc., purified, separted, and collected. A dose is >=100,000 units daily.
Otosclerosis is an inflammatory bone remodeling disorder of the otic capsule, characterized by spongiotic new bone formation, causing stamped ankylosis that can result in conductive hearing loss. Until now, the gold standard imaging technique for diagnosis and pre-operative evaluation of otosclerosis has been multi-detector computed tomography (MDCT). Cone Beam computed tomography is a relatively recent imaging modality. It is associated with a lower radiation dosage compared to MDCT, and a high spatial resolution that allows a more precise analysis of bone structures. During the last 15 years, its use has been increasingly common in odontology and craniofacial surgery. Several studies have already studied the utility of Cone Beam for temporal bone pathologies, including recent retrospective studies that showed satisfying diagnostic performances for otosclerosis. Up to now, very few prospective studies have compared those two imaging modalities for otosclerosis diagnosis and pre-operative evaluation.

Therefore, those two exams will be performed in patients addressed to the hospital for conductive hearing loss with intact tympanic membrane. Thus, the performance of Cone Beam will be compared to MDCT, regarding the positive diagnosis of otosclerosis, the analysis of anatomical structures of the temporal bone for pre-operative evaluation, and also the benefits in terms of irradiation. The MDCTs will include fewer slices than routine MDCTs and will be centered on the area of interest, in order to keep a total radiation dosage smaller or equivalent to routine care
Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
The invention belongs to the field of cosmetics, and particularly relates to application of a composition with an alopecia preventing effect in scalp essence and a preparation method thereof. The invention provides a complex formed by diaminopyrimidine oxide and zinc salt, wherein the molar ratio of the diaminopyrimidine oxide to the zinc salt is 1: 1-3: 1. In the research process, the inventor finds that the diaminopyrimidine oxide and zinc chloride are added into the anti-hair-loss formula at the same time, so that the anti-hair-loss effect is synergistic. The inventors have discovered, unintentionally, that this good result is achieved because the diaminopyrimidine oxide and zinc chloride contained in the anti-hair loss or hair-care formulation form a complex. Such an effect of the present invention cannot be achieved by removing either diaminopyrimidine oxide or zinc chloride. Therefore, according to the discovery, the zinc chloride of the diaminopyrimidine oxide is adjusted according to the proportion of the formed complex, so that a better anti-hair loss effect can be better achieved.